These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 31411768)

  • 21. Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.
    Bilezikian JP; Hattersley G; Fitzpatrick LA; Harris AG; Shevroja E; Banks K; Leder BZ; Zanchetta JR; Hans D
    Osteoporos Int; 2018 Feb; 29(2):323-328. PubMed ID: 29167971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug efficacies on bone mineral density and fracture rate for the treatment of postmenopausal osteoporosis: a network meta-analysis.
    Yang L; Kang N; Yang JC; Su QJ; Liu YZ; Guan L; Liu T; Meng XL; Wang Y; Hai Y
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(6):2640-2668. PubMed ID: 30964193
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Effect of Abaloparatide-SC on Fracture Risk Is Independent of Baseline FRAX Fracture Probability: A Post Hoc Analysis of the ACTIVE Study.
    McCloskey EV; Johansson H; Oden A; Harvey NC; Jiang H; Modin S; Fitzpatrick L; Kanis JA
    J Bone Miner Res; 2017 Aug; 32(8):1625-1631. PubMed ID: 28474780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis.
    Reginster J-; Bianic F; Campbell R; Martin M; Williams SA; Fitzpatrick LA
    Osteoporos Int; 2019 Jul; 30(7):1465-1473. PubMed ID: 30953114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proximal Femur Responses to Sequential Therapy With Abaloparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis by 3D Modeling of Hip Dual-Energy X-Ray Absorptiometry (DXA).
    Winzenrieth R; Kostenuik P; Boxberger J; Wang Y; Humbert L
    JBMR Plus; 2022 Apr; 6(4):e10612. PubMed ID: 35434451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study.
    Dhaliwal R; Hans D; Hattersley G; Mitlak B; Fitzpatrick LA; Wang Y; Schwartz AV; Miller PD; Josse RG
    JBMR Plus; 2020 Apr; 4(4):e10346. PubMed ID: 32258965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abaloparatide: A new pharmacological option for osteoporosis.
    Sleeman A; Clements JN
    Am J Health Syst Pharm; 2019 Jan; 76(3):130-135. PubMed ID: 30689744
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-Score as an Indicator of Fracture Risk During Treatment With Romosozumab or Alendronate in the ARCH Trial.
    Cosman F; Lewiecki EM; Ebeling PR; Hesse E; Napoli N; Matsumoto T; Crittenden DB; Rojeski M; Yang W; Libanati C; Ferrari S
    J Bone Miner Res; 2020 Jul; 35(7):1333-1342. PubMed ID: 32445228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Abaloparatide for the treatment of postmenopausal osteoporosis.
    Pietrogrande L; Raimondo E
    Drugs Today (Barc); 2018 May; 54(5):293-303. PubMed ID: 29911694
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy of bone anabolic therapies in women with postmenopausal osteoporosis: A systematic review and network meta-analysis of randomized controlled trials.
    Hernandez AV; Pérez-López FR; Piscoya A; Pasupuleti V; Roman YM; Thota P; Herrera A
    Maturitas; 2019 Nov; 129():12-22. PubMed ID: 31547908
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
    Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
    Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abaloparatide: A review of preclinical and clinical studies.
    Brent MB
    Eur J Pharmacol; 2021 Oct; 909():174409. PubMed ID: 34364879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Abaloparatide Increases Lumbar Spine and Hip BMD in Japanese Patients With Osteoporosis: The Phase 3 ACTIVE-J Study.
    Matsumoto T; Sone T; Soen S; Tanaka S; Yamashita A; Inoue T
    J Clin Endocrinol Metab; 2022 Sep; 107(10):e4222-e4231. PubMed ID: 35977548
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
    Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment with alendronate prevents fractures in women at highest risk: results from the Fracture Intervention Trial.
    Ensrud KE; Black DM; Palermo L; Bauer DC; Barrett-Connor E; Quandt SA; Thompson DE; Karpf DB
    Arch Intern Med; 1997 Dec 8-22; 157(22):2617-24. PubMed ID: 9531231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial.
    Cosman F; Peterson LR; Towler DA; Mitlak B; Wang Y; Cummings SR
    J Clin Endocrinol Metab; 2020 Nov; 105(11):3384-95. PubMed ID: 32658264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG; Weiss S; McClung M; Schnitzer T; Cerchio K; Connor J; Krupa D; Gertz BJ;
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
    McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
    Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group.
    Pols HA; Felsenberg D; Hanley DA; Stepán J; Muñoz-Torres M; Wilkin TJ; Qin-sheng G; Galich AM; Vandormael K; Yates AJ; Stych B
    Osteoporos Int; 1999; 9(5):461-8. PubMed ID: 10550467
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Summary of AHRQ's comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report.
    Levis S; Theodore G
    J Manag Care Pharm; 2012 May; 18(4 Suppl B):S1-15; discussion S13. PubMed ID: 22716221
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.